136 related articles for article (PubMed ID: 21474353)
1. A safety trial of high dose glyceryl triacetate for Canavan disease.
Segel R; Anikster Y; Zevin S; Steinberg A; Gahl WA; Fisher D; Staretz-Chacham O; Zimran A; Altarescu G
Mol Genet Metab; 2011 Jul; 103(3):203-6. PubMed ID: 21474353
[TBL] [Abstract][Full Text] [Related]
2. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
[TBL] [Abstract][Full Text] [Related]
3. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.
Madhavarao CN; Arun P; Anikster Y; Mog SR; Staretz-Chacham O; Moffett JR; Grunberg NE; Gahl WA; Namboodiri AMA
J Inherit Metab Dis; 2009 Oct; 32(5):640. PubMed ID: 19685155
[TBL] [Abstract][Full Text] [Related]
4. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
[TBL] [Abstract][Full Text] [Related]
5. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
6. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Tsen AR; Long PM; Driscoll HE; Davies MT; Teasdale BA; Penar PL; Pendlebury WW; Spees JL; Lawler SE; Viapiano MS; Jaworski DM
Int J Cancer; 2014 Mar; 134(6):1300-10. PubMed ID: 23996800
[TBL] [Abstract][Full Text] [Related]
7. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
8. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
9. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
10. Metabolic acetate therapy for the treatment of traumatic brain injury.
Arun P; Ariyannur PS; Moffett JR; Xing G; Hamilton K; Grunberg NE; Ives JA; Namboodiri AM
J Neurotrauma; 2010 Jan; 27(1):293-8. PubMed ID: 19803785
[TBL] [Abstract][Full Text] [Related]
11. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
12. Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest.
Long PM; Tighe SW; Driscoll HE; Fortner KA; Viapiano MS; Jaworski DM
J Cell Physiol; 2015 Aug; 230(8):1929-43. PubMed ID: 25573156
[TBL] [Abstract][Full Text] [Related]
13. Atypical clinical and radiological course of a patient with Canavan disease.
Sarret C; Boespflug-Tanguy O; Rodriguez D
Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
[TBL] [Abstract][Full Text] [Related]
14. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly.
Topçu M; Yalnizoğlu D; Saatçi I; Haliloğlu G; Topaloğlu H; Senbil N; Onol S; Coşkun T
Turk J Pediatr; 2004; 46(1):67-71. PubMed ID: 15074377
[TBL] [Abstract][Full Text] [Related]
15. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
16. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
17. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
18. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
[TBL] [Abstract][Full Text] [Related]
19. Lithium citrate as treatment of Canavan disease.
Solsona MD; Fernández LL; Boquet EM; Andrés JL
Clin Neuropharmacol; 2012; 35(3):150-1. PubMed ID: 22592512
[TBL] [Abstract][Full Text] [Related]
20. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]